Advertisement

Coffee consumption and risk of bladder cancer: a pooled analysis of 501,604 participants from 12 cohort studies in the BLadder Cancer Epidemiology and Nutritional Determinants (BLEND) international study

  • Evan Y. W. Yu
  • Yanan Dai
  • Anke WesseliusEmail author
  • Frits van Osch
  • Maree Brinkman
  • Piet van den Brandt
  • Eric J. Grant
  • Emily White
  • Elisabete Weiderpass
  • Marc Gunter
  • Bertrand Hemon
  • Maurice P. Zeegers
META-ANALYSIS

Abstract

Recent epidemiological studies have shown varying associations between coffee consumption and bladder cancer (BC). This research aims to elucidate the association between coffee consumption and BC risk by bringing together worldwide cohort studies on this topic. Coffee consumption in relation to BC risk was examined by pooling individual data from 12 cohort studies, comprising of 2601 cases out of 501,604 participants. Pooled multivariate hazard ratios (HRs), with corresponding 95% confidence intervals (CIs), were obtained using multilevel Weibull regression models. Furthermore, dose–response relationships were examined using generalized least squares regression models. The association between coffee consumption and BC risk showed interaction with sex (P-interaction < 0.001) and smoking (P-interaction = 0.001). Therefore, analyses were stratified by sex and smoking. After adjustment for potential confounders, an increased BC risk was shown for high (> 500 ml/day, equivalent to > 4 cups/day) coffee consumption compared to never consumers among male smokers (current smokers: HR = 1.75, 95% CI 1.27–2.42, P-trend = 0.002; former smokers: HR = 1.44, 95% CI 1.12–1.85, P-trend = 0.001). In addition, dose–response analyses, in male smokers also showed an increased BC risk for coffee consumption of more than 500 ml/day (4 cups/day), with the risk of one cup (125 ml) increment as 1.07 (95% CI 1.06–1.08). This research suggests that positive associations between coffee consumption and BC among male smokers but not never smokers and females. The inconsistent results between sexes and the absence of an association in never smokers indicate that the associations found among male smokers is unlikely to be causal and is possibly caused by residual confounding of smoking.

Keywords

Bladder cancer Coffee consumption Smoking Dose–response analyses Cohort study 

Abbreviations

BLEND

BLadder Cancer Epidemiology and Nutritional Determinants

BC

Bladder cancer

GLS

Generalized least squares

IARC

International Agency for Research on Cancer

EPIC

European Prospective Investigation into Cancer and Nutrition Cohort Studies

NLCS

NetherLands Cohort Study

VITAL

VITamins And Lifestyle cohort study

RERF-LSS

Radiation Effects Research Foundation-Life Span Study

FFQ

Food frequency questionnaires

ICD-O

International classification of diseases for oncology

NMIBC

Non-muscle invasive bladder cancer

MIBC

Muscle invasive bladder cancer

HR

Hazard ratio

CI

Confidence interval

CYP1A2

Cytochrome P450 1A2

PAHs

Polycyclic aromatic hydrocarbons

ATM

Ataxia-telangiectasia mutated

BMI

Body Mass Index

SES

Socioeconomic status

ml

Millilitre

kcal

Kilocalorie

g

Gram

mg

Microgram

Notes

Acknowledgements

We gratefully acknowledge all principal investigators for their willingness to participate in this jointed project. The author E Y.W. Yu gives thanks to the financial support from China Scholarship Council (No. 201706310135).

Author contributions

Study conception and design: AW and MPZ; Analyses and interpretation of data: EYY and YD; Drafting of the manuscript: EYY and YD; Revised the manuscript: AW, FVO, MB and MPZ; Provided the data: PvdB, EG, EW, EW, MG, BH; Approved the manuscript: all authors.

Funding

This work was partly funded by the World Cancer Research Fund International (WCRF 2012/590) and European Commission (FP7-PEOPLE-618308). The NetherLands Cohort Study on diet and cancer was supported by the Dutch Cancer Society. The RERF atomic bomb survivors Study was supported by The Radiation Effects Research Foundation (RERF), Hiroshima and Nagasaki, Japan, a public interest foundation funded by the Japanese Ministry of Health, Labour and Welfare (MHLW) and the US Department of Energy (DOE). The research was also funded in part through DOE award DE-HS0000031 to the National Academy of Sciences. This publication was supported by RERF Research Protocol RP-A5-12. The VITamins and Lifestyle Study (VITAL) was supported by a Grant (R01CA74846) from the National Cancer Institute. The European Prospective Investigation into Cancer and Nutrition (EPIC) was carried out with financial support of the ‘Europe Against Cancer’ Programme of the European Commission (SANCO); Ligue contre le Cancer (France); Société 3 M (France); Mutuelle Générale de l’Éducation Nationale; Institut National de la Santé et de la Recherche Médicale (INSERM); Institute Gustave Roussy; German Cancer Aid; German Cancer Research Centre; German Federal Ministry of Education and Research; Health Research Fund (FIS) of the Spanish Ministry of Health; the Spanish Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra; Cancer Research UK; Medical Research Council, UK; Stroke Association, UK; British Heart Foundation; Department of Health, UK; Food Standards Agency, UK; Wellcome Trust, UK; Greek Ministry of Health; Greek Ministry of Education; Italian Association for Research on Cancer; Italian National Research Council; Dutch Ministry of Public Health, Welfare and Sports; Dutch Prevention Funds; LK Research Funds; Dutch ZON (Zorg Onderzoek Nederland); World Cancer Research Fund; Swedish Cancer Society; Swedish Scientific Council; Regional Government of Skane, Sweden; Norwegian Cancer Society; Norwegian Research Council. Partial support for the publication of this supplement was provided by the Centre de Recherche et d’Information Nutritionnelles (CERIN).

Compliance with ethical standards

Conflict of interest

All the authors declare no conflict of interest.

Ethics approval and consent to participate

Each participating study has been approved by the local ethic committee. Informed consent was obtained from all individual participants included in each study.

Supplementary material

10654_2019_597_MOESM1_ESM.docx (375 kb)
Supplementary material 1 (DOCX 375 kb)

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.  https://doi.org/10.3322/caac.21387.CrossRefPubMedGoogle Scholar
  2. 2.
    Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108.  https://doi.org/10.1016/j.eururo.2016.06.010.CrossRefPubMedGoogle Scholar
  3. 3.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.  https://doi.org/10.3322/caac.20107.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27(3):289–93.  https://doi.org/10.1007/s00345-009-0383-3.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Marugame T, Mizuno S. Comparison of prostate cancer mortality in five countries: France, Italy, Japan, UK and USA from the WHO mortality database (1960–2000). Jpn J Clin Oncol. 2005;35(11):690–1.  https://doi.org/10.1093/jjco/hyi185.CrossRefPubMedGoogle Scholar
  6. 6.
    Stewart B, Wild CP. World cancer report 2014. New York: International Agency for Research on Cancer, World Health Organization: WHO Press; 2017.Google Scholar
  7. 7.
    Letašiová S, Medveďová A, Šovčíková A, et al. Bladder cancer, a review of the environmental risk factors. Environ Health. 2012;11(Suppl 1):S11.  https://doi.org/10.1186/1476-069X-11-S1-S11.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer. Pharmacoeconomics. 2003;21(18):1315–30.  https://doi.org/10.1007/BF03262330.CrossRefPubMedGoogle Scholar
  9. 9.
    Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin Surg Oncol. 1997;13(5):291–8.  https://doi.org/10.1002/(sici)1098-2388(199709/10)13:5%3c291:aid-ssu2%3e3.0.co;2-8.CrossRefPubMedGoogle Scholar
  10. 10.
    Thun M, Linet MS, Cerhan JR, Haiman CA, Schottenfeld D. Cancer epidemiology and prevention. 3rd ed. Oxford: Oxford University Press; 2017.  https://doi.org/10.1093/ije/dyy166.CrossRefGoogle Scholar
  11. 11.
    Cole P. Coffee-drinking and cancer of the lower urinary tract. Lancet. 1971;1(7713):1335–7.  https://doi.org/10.1016/S0140-6736(71)91890-3.CrossRefPubMedGoogle Scholar
  12. 12.
    Nagano J, Kono S, Preston DL, Moriwaki H, Sharp GB, Koyama K, et al. Bladder-cancer incidence in relation to vegetable and fruit consumption: a prospective study of atomic-bomb survivors. Int J Cancer. 2000;86(1):132–8.  https://doi.org/10.1002/(sici)1097-0215(20000401)86:1%3c132:aid-ijc21%3e3.0.co;2-m.CrossRefPubMedGoogle Scholar
  13. 13.
    Pujolar AE, Gonzalez CA, Lopez-Abente G, Errezola M, Izarzugaza I, Nebot M, et al. Bladder cancer and coffee consumption in smokers and non-smokers in Spain. Int J Epidemiol. 1993;22(1):38–44.  https://doi.org/10.1093/ije/22.1.38.CrossRefGoogle Scholar
  14. 14.
    Bruemmer B, White E, Vaughan TL, Cheney CL. Fluid intake and the incidence of bladder cancer among middle-aged men and women in a three-county area of western Washington. Nutr Cancer. 1997;29(2):163–8.  https://doi.org/10.1080/01635589709514619.CrossRefPubMedGoogle Scholar
  15. 15.
    Demirel F, Cakan M, Yalçınkaya F, Topcuoglu M, Altug U. The association between personal habits and bladder cancer in Turkey. Int Urol Nephrol. 2008;40(3):643–7.  https://doi.org/10.1007/s11255-008-9331-1.CrossRefPubMedGoogle Scholar
  16. 16.
    Kobeissi LH, Yassine IA, Jabbour ME, Moussa MA, Dhaini HR. Urinary bladder cancer risk factors: a Lebanese case–control study. Asian Pac J Cancer Prev APJCP. 2013;14(5):3205–11.  https://doi.org/10.7314/apjcp.2013.14.5.3205.CrossRefPubMedGoogle Scholar
  17. 17.
    Sugiyama K, Sugawara Y, Tomata Y, Nishino Y, Fukao A, Tsuji I. The association between coffee consumption and bladder cancer incidence in a pooled analysis of the Miyagi Cohort Study and Ohsaki Cohort Study. Eur J Cancer Prev. 2017;26(2):125–30.  https://doi.org/10.1097/cej.0000000000000226.CrossRefPubMedGoogle Scholar
  18. 18.
    Kurahashi N, Inoue M, Iwasaki M, Sasazuki S, Tsugane S. Coffee, green tea, and caffeine consumption and subsequent risk of bladder cancer in relation to smoking status: a prospective study in Japan. Cancer Sci. 2009;100(2):284–91.  https://doi.org/10.1111/j.1349-7006.2008.01027.x.CrossRefGoogle Scholar
  19. 19.
    Vena JE, Freudenheim J, Graham S, Marshall J, Zielezny M, Swanson M, et al. Coffee, cigarette smoking, and bladder cancer in western New York. Ann Epidemiol. 1993;3(6):586–91.  https://doi.org/10.1016/1047-2797(93)90079-J.CrossRefPubMedGoogle Scholar
  20. 20.
    Geoffroy-Perez B, Cordier S. Fluid consumption and the risk of bladder cancer: results of a multicenter case–control study. Int J Cancer. 2001;93(6):880–7.  https://doi.org/10.1002/ijc.1411.CrossRefPubMedGoogle Scholar
  21. 21.
    De Stefani E, Boffetta P, Deneo-Pellegrini H, Correa P, Ronco AL, Brennan P, et al. Non-alcoholic beverages and risk of bladder cancer in Uruguay. BMC Cancer. 2007;7:57.  https://doi.org/10.1186/1471-2407-7-57.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Mills PK, Beeson WL, Phillips RL, Fraser GE. Bladder cancer in a low risk population: results from the Adventist Health Study. Am J Epidemiol. 1991;133(3):230–9.  https://doi.org/10.1093/oxfordjournals.aje.a115867.CrossRefPubMedGoogle Scholar
  23. 23.
    Chyou P-H, Nomura AM, Stemmermann GN. A prospective study of diet, smoking, and lower urinary tract cancer. Ann Epidemiol. 1993;3(3):211–6.  https://doi.org/10.1016/1047-2797(93)90021-U.CrossRefPubMedGoogle Scholar
  24. 24.
    Tripathi A, Folsom AR, Anderson KE. Risk factors for urinary bladder carcinoma in postmenopausal women. Cancer. 2002;95(11):2316–23.  https://doi.org/10.1002/cncr.10975.CrossRefPubMedGoogle Scholar
  25. 25.
    Loftfield E, Freedman ND, Inoue-Choi M, Graubard BI, Sinha R. A prospective investigation of coffee drinking and bladder cancer incidence in the United States. Epidemiology. 2017;28(5):685–93.  https://doi.org/10.1097/ede.0000000000000676.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Loomis D, Guyton KZ, Grosse Y, et al. Carcinogenicity of drinking coffee, mate, and very hot beverages. Lancet Oncol. 2016;17(7):877–8.  https://doi.org/10.1016/S1470-2045(16)30239-X.CrossRefPubMedGoogle Scholar
  27. 27.
    Swanson JA, Lee JW, Hopp JW. Caffeine and nicotine: a review of their joint use and possible interactive effects in tobacco withdrawal. Addict Behav. 1994;19(3):229–56.  https://doi.org/10.1016/0306-4603(94)90027-2.CrossRefPubMedGoogle Scholar
  28. 28.
    Zhou Y, Tian C, Jia C. A dose–response meta-analysis of coffee consumption and bladder cancer. Prev Med. 2012;55(1):14–22.  https://doi.org/10.1016/j.ypmed.2012.04.020.CrossRefPubMedGoogle Scholar
  29. 29.
    Benowitz NL, Peng M, Jacob P. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin Pharmacol Ther. 2003;74(5):468–74.  https://doi.org/10.1016/j.clpt.2003.07.001.CrossRefPubMedGoogle Scholar
  30. 30.
    Zevin S, Benowitz NL. Drug interactions with tobacco smoking. Clin Pharmacokinet. 1999;36(6):425–38.  https://doi.org/10.2165/00003088-199936060-00004.CrossRefPubMedGoogle Scholar
  31. 31.
    De Leon J, Diaz FJ, Rogers T, et al. A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(1):165–71.  https://doi.org/10.1016/S0278-5846(02)00348-2.CrossRefPubMedGoogle Scholar
  32. 32.
    Plowchalk DR, Yeo KR. Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. Eur J Clin Pharmacol. 2012;68(6):951–60.  https://doi.org/10.1007/s00228-011-1189-y.CrossRefPubMedGoogle Scholar
  33. 33.
    Yu EY, Wesselius A, van Osch F, Stern MC, Jiang X, Kellen E, et al. The association between coffee consumption and bladder cancer in the Bladder Cancer Epidemiology and Nutritional Determinants (BLEND) international pooled study. Cancer Causes Control CCC. 2019.  https://doi.org/10.1007/s10552-019-01191-1.CrossRefPubMedGoogle Scholar
  34. 34.
    Riboli E, Kaaks R. The EPIC project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol. 1997;26(Suppl 1):S6–14.  https://doi.org/10.1093/ije/26.suppl_1.s6.CrossRefPubMedGoogle Scholar
  35. 35.
    Clavel-Chapelon F, van Liere MJ, Giubout C, Niravong MY, Goulard H, Le Corre C, et al. E3N, a French cohort study on cancer risk factors. E3N Group Etude Epidemiologique aupres de femmes de l’Education Nationale Eur J Cancer Prev. 1997;6(5):473–8.  https://doi.org/10.1097/00008469-199710000-00007.CrossRefPubMedGoogle Scholar
  36. 36.
    Boeing H, Korfmann A, Bergmann MM. Recruitment procedures of EPIC-Germany. European Investigation into Cancer and Nutrition. Ann Nutr Metab. 1999;43(4):205–15.  https://doi.org/10.1159/000012787.CrossRefPubMedGoogle Scholar
  37. 37.
    Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5(6b):1113–24.  https://doi.org/10.1079/phn2002394.CrossRefPubMedGoogle Scholar
  38. 38.
    Panico S, Dello Iacovo R, Celentano E, Galasso R, Muti P, Salvatore M, et al. Progetto ATENA, a study on the etiology of major chronic diseases in women: design, rationale and objectives. Eur J Epidemiol. 1992;8(4):601–8.CrossRefGoogle Scholar
  39. 39.
    Beulens JW, Monninkhof EM, Verschuren WM, van der Schouw YT, Smit J, Ocke MC, et al. Cohort profile: the EPIC-NL study. Int J Epidemiol. 2010;39(5):1170–8.  https://doi.org/10.1093/ije/dyp217.CrossRefPubMedGoogle Scholar
  40. 40.
    Lund E, Dumeaux V, Braaten T, Hjartaker A, Engeset D, Skeie G, et al. Cohort profile: The Norwegian Women and Cancer Study–NOWAC–Kvinner og kreft. Int J Epidemiol. 2008;37(1):36–41.  https://doi.org/10.1093/ije/dym137.CrossRefPubMedGoogle Scholar
  41. 41.
    Manjer J, Carlsson S, Elmstahl S, Gullberg B, Janzon L, Lindstrom M, et al. The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev. 2001;10(6):489–99.  https://doi.org/10.1097/00008469-200112000-00003.CrossRefPubMedGoogle Scholar
  42. 42.
    Hallmans G, Agren A, Johansson G, Johansson A, Stegmayr B, Jansson JH, et al. Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort—evaluation of risk factors and their interactions. Scand J Public Health Suppl. 2003;61:18–24.  https://doi.org/10.1080/14034950310001432.CrossRefPubMedGoogle Scholar
  43. 43.
    Davey GK, Spencer EA, Appleby PN, Allen NE, Knox KH, Key TJ. EPIC-Oxford: lifestyle characteristics and nutrient intakes in a cohort of 33 883 meat-eaters and 31 546 non meat-eaters in the UK. Public Health Nutr. 2003;6(3):259–69.  https://doi.org/10.1079/phn2002430.CrossRefPubMedGoogle Scholar
  44. 44.
    Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer. 1999;80(Suppl 1):95–103.PubMedGoogle Scholar
  45. 45.
    van den Brandt PA, Goldbohm RA, van’t Veer P, Volovics A, Hermus RJ, Sturmans F. A large-scale prospective cohort study on diet and cancer in The Netherlands. J Clin Epidemiol. 1990;43(3):285–95.  https://doi.org/10.1016/0895-4356(90)90009-e.CrossRefPubMedGoogle Scholar
  46. 46.
    White E, Patterson RE, Kristal AR, Thornquist M, King I, Shattuck AL, et al. VITamins and lifestyle cohort study: study design and characteristics of supplement users. Am J Epidemiol. 2004;159(1):83–93.  https://doi.org/10.1093/aje/kwh010.CrossRefPubMedGoogle Scholar
  47. 47.
    Ozasa K, Shimizu Y, Sakata R, Sugiyama H, Grant EJ, Soda M, et al. Risk of cancer and non-cancer diseases in the atomic bomb survivors. Radiat Prot Dosimetry. 2011;146(1–3):272–5.  https://doi.org/10.1093/rpd/ncr168.CrossRefPubMedGoogle Scholar
  48. 48.
    Radiation Effects Research Foundation Ethics Committee. https://www.rerforjp/en/programs/general_research_e/committee/. Accessed 15 July, 2019.
  49. 49.
    Goossens ME, Isa F, Brinkman M, et al. International pooled study on diet and bladder cancer: the bladder cancer, epidemiology and nutritional determinants (BLEND) study: design and baseline characteristics. Arch Public Health. 2016;74(1):30–9.  https://doi.org/10.1186/s13690-016-0140-1.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Satia-Abouta J, Patterson RE, King IB, Stratton KL, Shattuck AL, Kristal AR, et al. Reliability and validity of self-report of vitamin and mineral supplement use in the vitamins and lifestyle study. Am J Epidemiol. 2003;157(10):944–54.  https://doi.org/10.1093/aje/kwg039.CrossRefPubMedGoogle Scholar
  51. 51.
    Zeegers MP, Goldbohm RA, van den Brandt PA. Are retinol, vitamin C, vitamin E, folate and carotenoids intake associated with bladder cancer risk? Results from the NetherLands Cohort Study. Br J Cancer. 2001;85(7):977–83.  https://doi.org/10.1054/bjoc.2001.1968.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Sauvaget C, Allen N, Hayashi M, Spencer E, Nagano J. Validation of a food frequency questionnaire in the Hiroshima/Nagasaki Life Span Study. J Epidemiol. 2002;12(5):394–401.  https://doi.org/10.2188/jea.12.394.CrossRefPubMedGoogle Scholar
  53. 53.
    Ferrari P, Slimani N, Ciampi A, Trichopoulou A, Naska A, Lauria C, et al. Evaluation of under- and overreporting of energy intake in the 24-hour diet recalls in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr. 2002;5(6b):1329–45.  https://doi.org/10.1079/phn2002409.CrossRefPubMedGoogle Scholar
  54. 54.
    Poortvliet E, Klensin J, Kohlmeier L. Rationale document for the Eurocode 2 food coding system (version 91/2). Eur J Clin Nutr. 1992;46(Suppl 5):S9–24.PubMedGoogle Scholar
  55. 55.
    Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-analysis for linear and nonlinear dose–response relations: examples, an evaluation of approximations, and software. Am J Epidemiol. 2012;175(1):66–73.  https://doi.org/10.1093/aje/kwr265.CrossRefPubMedGoogle Scholar
  56. 56.
    Desquilbet L, Mariotti F. Dose–response analyses using restricted cubic spline functions in public health research. Stat Med. 2010;29(9):1037–57.  https://doi.org/10.1002/sim.3841.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Istvan J, Matarazzo JD. Tobacco, alcohol, and caffeine use: a review of their interrelationships. Psychol Bull. 1984;95(2):301–26.  https://doi.org/10.1037/0033-2909.95.2.301.CrossRefPubMedGoogle Scholar
  58. 58.
    Emurian HH, Nellis MJ, Brady JV, Ray RL. Event time-series relationship between cigarette smoking and coffee drinking. Addict Behav. 1982;7(4):441–4.  https://doi.org/10.1016/0306-4603(82)90016-8.CrossRefPubMedGoogle Scholar
  59. 59.
    Lane JD. Association of coffee drinking with cigarette smoking in the natural environment. Exp Clin Psychopharmacol. 1996;4(4):409.  https://doi.org/10.1037/1064-1297.4.4.409.CrossRefGoogle Scholar
  60. 60.
    Brown CR, Jacob P 3rd, Wilson M, Benowitz NL. Changes in rate and pattern of caffeine metabolism after cigarette abstinence. Clin Pharmacol Ther. 1988;43(5):488–91.  https://doi.org/10.1038/clpt.1988.63.CrossRefPubMedGoogle Scholar
  61. 61.
    Swanson JA, Lee JW, Hopp JW, Berk LS. The impact of caffeine use on tobacco cessation and withdrawal. Addict Behav. 1997;22(1):55–68.  https://doi.org/10.1016/S0306-4603(96)00023-8.CrossRefPubMedGoogle Scholar
  62. 62.
    Langmann P, Bienert A, Zilly M, Väth T, Richter E, Klinker H. Influence of smoking on cotinine and caffeine plasma levels in patients with alcoholic liver cirrhosis. Eur J Med Res. 2000;5(5):217–21.PubMedGoogle Scholar
  63. 63.
    Ossip DJ, Epstein LH. Relative effects of nicotine and coffee on cigarette smoking. Addict Behav. 1981;6(1):35–9.  https://doi.org/10.1016/S0306-4603(81)80006-8.CrossRefPubMedGoogle Scholar
  64. 64.
    Landi M, Sinha R, Lang N, Kadlubar F. Human cytochrome P4501A2. IARC Sci Publ. 1999;148:173–95.Google Scholar
  65. 65.
    Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther. 1991;50(5–1):508–19.CrossRefGoogle Scholar
  66. 66.
    Gunes A, Dahl M-L. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics. 2008;9(5):625–37.  https://doi.org/10.2217/14622416.9.5.625.CrossRefPubMedGoogle Scholar
  67. 67.
    Yu EY, Wesselius A, van Osch F, Stern MC, Jiang X, Kellen E, et al. The association between coffee consumption and bladder cancer in the Bladder Cancer Epidemiology and Nutritional Determinants (BLEND) international pooled study. Cancer Causes Control CCC. 2019;30(8):859–70.  https://doi.org/10.1007/s10552-019-01191-1.CrossRefPubMedGoogle Scholar
  68. 68.
    Hashemian M, Sinha R, Murphy G, Weinstein SJ, Liao LM, Freedman ND, et al. Coffee and tea drinking and risk of cancer of the urinary tract in male smokers. Ann Epidemiol. 2019.  https://doi.org/10.1016/j.annepidem.2019.03.014.CrossRefPubMedGoogle Scholar
  69. 69.
    Wu W, Tong Y, Zhao Q, Yu G, Wei X, Lu Q. Coffee consumption and bladder cancer: a meta-analysis of observational studies. Sci Rep. 2015;5:1–9.  https://doi.org/10.1038/srep09051.CrossRefGoogle Scholar
  70. 70.
    Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol. 2016;69(2):300–10.  https://doi.org/10.1016/j.eururo.2015.08.037.CrossRefPubMedGoogle Scholar
  71. 71.
    Rothwell JA, Loftfield E, Wedekind R, Freedman N, Kambanis C, Scalbert A, et al. A metabolomic study of the variability of the chemical composition of commonly consumed coffee brews. Metabolites. 2019.  https://doi.org/10.3390/metabo9010017.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Zhang Z-W, Xiao J, Luo W, Wang B-H, Chen J-M. Caffeine suppresses apoptosis of bladder cancer RT4 cells in response to ionizing radiation by inhibiting ataxia telangiectasia mutated-Chk2-p53 axis. Chin Med J. 2015;128(21):2938–45.  https://doi.org/10.4103/0366-6999.168065.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Sarkaria JN, Busby EC, Tibbetts RS, et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 1999;59(17):4375–82.PubMedGoogle Scholar
  74. 74.
    Tej G, Nayak PK. Mechanistic considerations in chemotherapeutic activity of caffeine. Biomed Pharmacother. 2018;105:312–9.  https://doi.org/10.1016/j.biopha.2018.05.144.CrossRefPubMedGoogle Scholar
  75. 75.
    Azam S, Hadi N, Khan NU, Hadi SM. Antioxidant and prooxidant properties of caffeine, theobromine and xanthine. Med Sci Monit Int Med J Exp Clin Res. 2003;9(9):Br325–30.Google Scholar
  76. 76.
    Venkata Charan Tej GN, Neogi K, Verma SS, Chandra Gupta S, Nayak PK. Caffeine-enhanced anti-tumor immune response through decreased expression of PD1 on infiltrated cytotoxic T lymphocytes. Eur J Pharmacol. 2019;859:172538.  https://doi.org/10.1016/j.ejphar.2019.172538.CrossRefPubMedGoogle Scholar
  77. 77.
    Maughan RJ, Griffin J. Caffeine ingestion and fluid balance: a review. J Hum Nutr Diet. 2003;16(6):411–20.  https://doi.org/10.1046/j.1365-277x.2003.00477.x.CrossRefPubMedGoogle Scholar
  78. 78.
    Renouf M, Marmet C, Guy P, Fraering AL, Longet K, Moulin J, et al. Nondairy creamer, but not milk, delays the appearance of coffee phenolic acid equivalents in human plasma. J Nutr. 2010;140(2):259–63.  https://doi.org/10.3945/jn.109.113027.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature B.V. 2020

Authors and Affiliations

  • Evan Y. W. Yu
    • 1
  • Yanan Dai
    • 1
  • Anke Wesselius
    • 1
    Email author
  • Frits van Osch
    • 1
  • Maree Brinkman
    • 1
    • 2
    • 3
  • Piet van den Brandt
    • 4
  • Eric J. Grant
    • 5
  • Emily White
    • 6
  • Elisabete Weiderpass
    • 7
  • Marc Gunter
    • 7
  • Bertrand Hemon
    • 7
  • Maurice P. Zeegers
    • 1
    • 8
    • 9
  1. 1.Department of Complex Genetics and Epidemiology, School of Nutrition and Translational Research in MetabolismMaastricht UniversityMaastrichtThe Netherlands
  2. 2.Department of Clinical Studies and Nutritional EpidemiologyNutrition Biomed Research InstituteMelbourneAustralia
  3. 3.Cancer Epidemiology DivisionCancer Council VictoriaMelbourneAustralia
  4. 4.Department of Epidemiology, Schools for Oncology and Developmental Biology and Public Health and Primary CareMaastricht University Medical CentreMaastrichtThe Netherlands
  5. 5.Department of EpidemiologyRadiation Effects Research FoundationHiroshimaJapan
  6. 6.Fred Hutchinson Cancer Research CenterSeattleUSA
  7. 7.International Agency for Research on Cancer World Health OrganizationLyonFrance
  8. 8.CAPHRI School for Public Health and Primary CareMaastricht UniversityMaastrichtThe Netherlands
  9. 9.School of Cancer SciencesUniversity of BirminghamBirminghamUK

Personalised recommendations